Ligand Pharmaceuticals Incorporated
LGND
Ранг среди акций
#3100
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Цена акции
$291.18
Последняя синхронизация: 2026-07-31
Рыночная капитализация
$5.84B
Изменение (1 день)
-1.73%
Изменение (1 год)
55.99%
Страна
US
Торговля Ligand Pharmaceuticals Incorporated (LGND)
Категория
Healthcare
Выручка компании Ligand Pharmaceuticals Incorporated (LGND)
Выручка на Jun 2026 TTM: $290.54M
Согласно последним финансовым отчетам Ligand Pharmaceuticals Incorporated, текущая выручка компании (TTM) составляет $290.54M. В 2023 году компания получила выручку $131.31M меньше, чем выручке в 2022 году, которая составила $196.25M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Ligand Pharmaceuticals Incorporated с 2000 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $290.54M | 73.84% |
| 2024 | $167.13M | 27.28% |
| 2023 | $131.31M | -33.09% |
| 2022 | $196.25M | -18.75% |
| 2021 | $241.54M | 47.68% |
| 2020 | $163.56M | 35.98% |
| 2019 | $120.28M | -52.17% |
| 2018 | $251.45M | 78.21% |
| 2017 | $141.10M | 29.48% |
| 2016 | $108.97M | 51.53% |
| 2015 | $71.91M | 11.43% |
| 2014 | $64.54M | 31.78% |
| 2013 | $48.97M | 56.03% |
| 2012 | $31.39M | 4.50% |
| 2011 | $30.04M | 27.61% |
| 2010 | $23.54M | -39.55% |
| 2009 | $38.94M | 42.56% |
| 2008 | $27.32M | 111.84% |
| 2007 | $12.89M | -90.85% |
| 2006 | $140.96M | -20.18% |
| 2005 | $176.61M | 8.01% |
| 2004 | $163.51M | 15.85% |
| 2003 | $141.14M | 46.05% |
| 2002 | $96.64M | 26.59% |
| 2001 | $76.34M | 58.68% |
| 2000 | $48.11M | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $12.62B | 4,245.09% |
US
|
|
| $2.23B | 666.84% |
US
|
|
| $15.74B | 5,318.95% |
AU
|
|
| $6.02B | 1,972.43% |
NL
|
|
| - | - |
CH
|
